| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
HLA-B*5701 Typing
Test Code19774
CPT Codes
81381
Includes
Additional testing by Sequence Based Typing (SBT) may be performed when necessary.
Preferred Specimen
5 mL whole blood collected in an EDTA (lavender-top) tube
Minimum Volume
3 mL
Other Acceptable Specimens
Whole blood collected in: sodium heparin (green-top) tube, EDTA (pink-top), EDTA (royal blue-top), or sodium citrate (light blue-top) tube
Instructions
A separate EDTA (lavender-top) tube must be submitted for all HLA testing. If submitted with any other test requiring an EDTA tube, please submit a separate tube for this test. Do not open tube.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Refrigerated: 7 days
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Received frozen • Clotted
Methodology
Polymerase Chain Reaction (PCR) • Sequence Specific Oligonucleotide Probes (SSO)
FDA Status
Typing performed by using AS-PCR with reflex to the FDA-cleared LABType® SSO Kit. The AS-PCR portion of the test was developed and its performance characteristics have been determined by Quest Diagnostics.
Setup Schedule
Set up: Daily; Report available: 6 days
Limitations
A negative result does not rule out the risk for ABC HSR and clinical vigilance should be maintained regardless of the result. The frequency of HLA/-B5701 is approximately 8% in Caucasians and 2% in African Americans.
Clinical Significance
Abacavir therapy for HIV treatment is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong association with the HLA-B*5701 Allele. HLA-B*5701 typing can be used for genetic risk stratification prior to initiation of Abacavir therapy.
